Media coverage about Humana (NYSE:HUM) has been trending somewhat positive this week, AlphaOne reports. The research group, a subsidiary of Accern, scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Humana earned a coverage optimism score of 0.16 on AlphaOne’s scale. AlphaOne also gave headlines about the insurance provider an impact score of 89 out of 100, indicating that recent news coverage is very likely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted AlphaOne’s rankings:
- Noteworthy Friday Option Activity: WYNN, HUM, GS (marketnewsvideo.com)
- HUMANA INC : Submission of Matters to a Vote of Security Holders (form 8-K) (4-traders.com)
- Humana Stock Falls on Downgrade at Jefferies (finance.yahoo.com)
- Will Thermo Fisher (TMO) Pull a Surprise in Q1 Earnings? (nasdaq.com)
- Humana CEO: Obamacare exit not about politics (finance.yahoo.com)
Several analysts have issued reports on the stock. Jefferies Group LLC cut shares of Humana from a “buy” rating to a “hold” rating and set a $221.00 target price on the stock. in a research note on Friday. CIBC reiterated an “outperform” rating on shares of Humana in a research note on Thursday, March 30th. Piper Jaffray Companies assumed coverage on shares of Humana in a research note on Tuesday, January 3rd. They issued an “overweight” rating and a $231.00 target price on the stock. Oppenheimer Holdings Inc. assumed coverage on shares of Humana in a research note on Thursday, March 30th. They issued an “outperform” rating and a $236.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $237.00 target price on the stock in a research note on Tuesday. Nine research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Humana has an average rating of “Buy” and a consensus price target of $210.56.
Humana (NYSE:HUM) traded down 0.27% during trading on Friday, hitting $213.67. 2,267,444 shares of the company traded hands. The stock has a market capitalization of $31.91 billion, a PE ratio of 52.50 and a beta of 0.91. The company’s 50 day moving average is $212.85 and its 200-day moving average is $199.93. Humana has a 52 week low of $150.00 and a 52 week high of $220.49.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, February 8th. The insurance provider reported $2.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.05 by $0.04. Humana had a net margin of 1.09% and a return on equity of 13.09%. The company earned $12.88 billion during the quarter, compared to analyst estimates of $13.55 billion. During the same period in the prior year, the firm earned $1.45 earnings per share. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. Analysts predict that Humana will post $10.94 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 31st. Investors of record on Friday, June 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend is Wednesday, June 28th. Humana’s dividend payout ratio (DPR) is presently 29.59%.
In related news, VP M Todoroff Christopher sold 24,140 shares of the company’s stock in a transaction dated Tuesday, February 21st. The shares were sold at an average price of $205.33, for a total value of $4,956,666.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce D. Broussard sold 104,256 shares of the company’s stock in a transaction dated Tuesday, February 21st. The stock was sold at an average price of $205.23, for a total transaction of $21,396,458.88. Following the completion of the sale, the chief executive officer now directly owns 155,108 shares of the company’s stock, valued at $31,832,814.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 319,632 shares of company stock valued at $65,897,204. 0.50% of the stock is owned by insiders.
WARNING: “Humana (HUM) Receiving Somewhat Positive Press Coverage, Analysis Finds” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/04/21/humana-hum-receiving-somewhat-positive-press-coverage-analysis-finds.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.